PREDICTORS OF THE USE OF GASTROPROTECTIVE AGENTS IN PATIENTS USING NSAID IN YOGYAKARTA INDONESIA
Abstract
Non Steroid Anti-Inflammatory (NSAID) is one type of AntiInflammatory drug that is used to treat pain in patients of osteoarthritis (OA) and rheumatoid arthritis (RA). The use of NSAIDs can cause gastrointestinal side effects. To prevent the side effects, NSAIDs are prescribed in combination with gastroprotective agent (GPA). The aim of the study is to determine the factors considered in the GPA prescription by the doctors in patients who have risk factors for gastric disorder due to NSAIDs use. This study was performed using a cross-sectional observational design. The data were collected retrospectively during a period of January to December 2010. The subjects were OA and RA patients considering the inclusion and exclusion criteria. The data included patient characteristics (gender, age, occupation, payment method, the primary diagnosis), prescription of NSAID, prescription of GPA, history of gastrointestinal disease, NSAID prescription with corticosteroids, prescription with antiplatelet. The data were processed descriptively and quantitatively, and analyzed statistically using chi-square and log. regression with 95% Confidence Interval. The results showed that there were correlation between some predictor factors with prescription of gastroprotective agent. These factors were women patient, patient age of ≥ 65 years, oxicam prescribing, diclofenac sodium prescribing, prescribing >1 type of NSAIDs, prescription of NSAID concomitant with corticosteroids, prescription of NSAID concomitant with antiplatelet, patients with history of gastrointestinal, prescribing NSAIDs with duration of ≥ 3 months. Patient with a history of gastrointestinal disease was the most predictor influential factor, with OR (odds ratio) of 3.6 (95% CI: 2.79 - 4.66). Predictor factor of patients with a history of dyspepsia possessed the highest OR {OR=4,29 (CI 95%: 3.23–5.7)}. It means that patients with a history of dyspepsia prescribed NSAIDs would have greater risk of 4.29 times to get GPA prescription than patients without a history of dyspepsia. Prescribing NSAIDs > 1 DDD (defined daily dose) had p value of 0.777, which means there was no relationship between GPA prescription with NSAIDs > 1 DDD prescription.
Key words: Gastroprotective Agent, Non-steroid anti-inflammatory, Osteoarthritis, Rheumatoid Arthritis
Full Text:
UntitledReferences
Altman, R.D., 2000, Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee, American College of Rheumatologyvol 43, No.9: 1905-1915.
Anonim, 2007, Laporan Kunjungan Pasien Rumah Sakit, Poli Geriatri, RSUP Dr. Sardjito, Yogyakarta.
Davies NM, Saleh, JY. 2000., Detection and prevention of NSAID-induced enteropathy. J. Pharm. Pharmaceut Sci;3:137-155
Dijk, K.N.V., ter Huurne, K., de Vries, C.S., van den Berg, P.B., Brouwers, J.R.B.J., and de Jong-van den Berg, L.T.W., 2002. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharmacy World & Science. 24 (3): 100-103.
Koncz, T.A., Lister S.P., dan Makinson G.T., 2008, Gastroprotection in patients prescribed non-slective NSAIDs, and the risk of related hospitalization, Curr Med Res Opin, 2008;24(12):3405-12.
Laine, L., 2002, The gastrointestinal effects of nonselective NSAIDs and COX-2–selective inhibitors, Semin Arthritis Rheum, 32(Suppl 1):25-32.
Lanza, F.L., Chan, F.K.L., dan Quigley, E.M.M., 2009, Guidelines for Prevention of NSAID-Related Ulcer Complications, The American Journal of Gastroenterology, 104, 728-738.
van der Linden, M.W., Gaugris, S., Kuipers, E.J., van Herk-Sukel, M.P., van den Bemt, B.J., Sen, S.S., Herings, R.M., 2009, COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors, Pharmaco epidemiol and Drug Safety, 2009 Oct;18(10):880-90.
DOI: http://dx.doi.org/10.14499/indonesianjpharm23iss1pp41-47
Refbacks
- There are currently no refbacks.
Copyright (c) 2017 INDONESIAN JOURNAL OF PHARMACY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Indonesian J Pharm indexed by:
View My Stats